Following tumour exome sequencing, Vivan Therapeutics generates fruit fly avatars of patients incorporating tumourigenic mutations. With robotics, they evaluate more than 1,200 FDA approved drugs - including non-cancer drugs - to identify drug combinations that significantly improve mortality in the avatar population. They then present the drug combinations to a tumour board who make the best treatment recommendation for the patient.
Focus: Drug discovery platform
Team: Laura Towart
Website: https://vivantx.com/
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.